Systematic review and network meta-analysis of approved medicines for the treatment of idiopathic pulmonary fibrosis

Figures & data

Figure 1. Flow chart of search results.

Table 1. Synthesis of the results and network quality assessment.

Outcome	Measure	Model type	Pirfenidone vs Placebo, estimate (95% CI)	Nintedanib vs Placebo, estimate (95% CI)	Pirfenidone vs Nintedanib, estimate (95% CI)	Mean residual deviance
Decline in percent predicted FVC ≥ 10%	OR	Random effect	0.54 (0.37–0.80) I^2 = 53%	0.59 (0.41–0.84) I^2 = 48%	0.91 (0.45–2.03)	12.17
					Low quality (⊕⊕OO)^a^,^b
Acute exacerbations	OR	Random effect	0.77 (0.26–2.28)	0.61 (0.20–1.90) I^2 = 77%	0.39 (0.00–15.53)	11.57
					(⊕⊕OO)^a^,^b
Mortality	OR	Random effect	0.68 (0.46–1.03) I^2 = 0%	0.70 (0.45–1.09) I^2 = 0%	0.93 (0.38–1.94)	14.76
					(⊕⊕OO)^b^,^c
Dropouts	OR	Random effect	1.27 (0.96–1.68) I^2 = 0%	1.61 (1.13–2.28) I^2 = 17%	0.75 (0.33–1.27)	24.11
					Low quality (⊕⊕OO)^a^,^b
Serious adverse events	OR	Random effect	1.00 (0.78–1.29) I^2 = 0%	0.99 (0.78–1.28) I^2 = 0%	1.02 (0.62–1.62)	11.51
					Moderate quality (⊕⊕⊕O)^b

^a Inconsistency;

^b Imprecision;

^c Poor quality of direct evidence.

⊕ indicator of quality; high (4/4) ,moderate (3/4) ,low (2/4) ,very low (1/4)

Figure 2. Risk of bias of individual studies.

Table 2. Results of NNTB/NNTH estimation.

	NNTB or NNTH	Pirfenidone vs Placebo	Nintedanib vs Placebo
Decline in percent predicted FVC ≥10%	NNTB	NNTB 9 (NNTB 7 to NNTB 22)	NNTB 9 (NNTB 6 to NNTB 23)
Dropouts	NNTH	NNTH 12 (NNTH 7 to NNTH 58)	NNTH 14 (NNTH 8 to NNTH 61)